Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Microb Pathog. 2011 May 7;51(3):133–141. doi: 10.1016/j.micpath.2011.04.009

The cyclic-AMP receptor protein (CRP) regulon in Aggregatibacter actinomycetemcomitans includes leukotoxin

Leigh A Feuerbacher 1, Alex Burgum 1, David Kolodrubetz 1,*
PMCID: PMC3120918  NIHMSID: NIHMS294703  PMID: 21575705

Abstract

The cyclic-AMP receptor protein (CRP) acts as a global regulatory protein among bacteria. Here, the CRP regulon has been defined in Aggregatibacter actinomycetemcomitans using microarray analysis of A. actinomycetemcomitans strain JP2 wild type cells compared to an isogenic crp deletion mutant. Genes whose expression levels changed at least 2-fold with p ≤ 0.05 were considered significant. Of the 300 genes identified as being CRP-regulated, 139 were CRP-activated, including leukotoxin, with the remaining being CRP-repressed. The 300 genes represent 14.2% of ORFs probed which is significantly higher than what has been reported for CRP regulons in other bacteria. If the CRP-regulated genes are put into 17 functional classes, all 17 categories had at least 1 CRP-regulated gene. Several functional categories, mainly transport and binding proteins and energy metabolism proteins, were disproportionately represented in the CRP-regulated subset of genes relative to their overall representation in the genome. This is similar to the patterns seen in other bacteria. Finally, quantitative RT-PCR was used to show that the leukotoxin RNA levels were repressed 16-fold in the CRP mutant indicating that CRP activates leukotoxin transcription. However, this regulation appears to be acting through another regulatory protein since the leukotoxin promoter, unlike ~129 other promoters of CRP-regulated genes, does not have a match to the consensus CRP binding site. Several candidate genes for this intermediary transcription factor have been identified in the CRP-regulon.

Keywords: Aggregatibacter actinomycetemcomitans, cyclic-AMP receptor protein, CRP regulon, leukotoxin

1. Introduction

The gram-negative capnophilic bacterium Aggregatibacter actinomycetemcomitans is a bacterial resident of the oral cavity that has been implicated in adult periodontal disease as well as in non-oral infections, such as endocarditis [14]. However, this bacterium is most often associated with localized aggressive periodontitis (LAP) [2,57]. LAP has an early onset in life, typically afflicting adolescents. The disease is usually localized to the first molars and central incisors and is characterized by rapid tissue and alveolar bone destruction and it may ultimately lead to tooth loss if left untreated [8,9].

A. actinomycetemcomitans expresses a number of potential virulence factors in order to initiate and cause disease [8, 10, 11]. The most studied virulence factor is the 116-kDa leukotoxin [12, 13], in part because strains which express high levels of leukotoxin are most often associated with disease [14]. This protein is thought to help A. actinomycetemcomitans avoid host cell defenses by targeting and killing human polymorphonuclear leukocytes, macrophages, [1518] and erythrocytes [19], although it may induce apoptosis of cells at lower concentrations [20]. Interestingly, leukotoxin-induced killing of macrophages proceeds through a novel mechanism that leads to the release of pro-inflammatory cytokines during macrophage cell death [21, 22]. Early on, it became clear that the various strains of A. actinomycetemcomitans could be broadly placed into two groups based upon their levels of leukotoxin; highly leukotoxic strains make 10–20 times as much leukotoxin as moderate/low leukotoxin-producing strains [23]. The difference in leukotoxin expression between these groups is not due to sequence changes in their leukotoxin promoter regions, but is, instead, due to a deletion of 528 bp in the 5’-non-coding region of the leukotoxin operon [24, 25]. The mechanism by which this difference in the mRNA leader between strains leads to altered leukotoxin RNA levels is not known. Not surprisingly, this virulence factor is also regulated by a number of different environmental conditions. For example, anaerobiosis results in the induction of leukotoxin transcription and protein synthesis [26, 27]. Fong et al. reported that the secreted AI2 product of the luxS gene, a gene involved in quorum sensing, induced leukotoxin activity 3-fold [28]. The localization of leukotoxin, but not its transcription, is influenced by iron concentration; the protein is cell-surface-associated in iron-rich media but most of the leukotoxin protein is secreted into the media if iron is limiting [29]. More recently, ptsH and ptsI, which encode proteins of the phosphotransferase system, were shown to be required for maximal leukotoxin RNA synthesis [30]. Several years ago, Mizoguchi et al. and Inoue et al. found that leukotoxin transcription is affected by carbon source; limiting concentrations of fermentable sugars increase leukotoxin production. In addition, they showed that cyclic-AMP (cAMP) levels were proportional to leukotoxin levels [31, 32] . Since, in E. coli, cAMP binds to the cAMP receptor protein (CRP) [33] which regulates transcription at promoters containing reasonable matches to the consensus sequence, TGTGA-N6-TCACA, it is reasonable to suggest that leukotoxin in A. actinomycetemcomitans may be regulated by catabolite repression and CRP.

However, sequence inspection indicates that there is no CRP binding site within the A. actinomycetemcomitans leukotoxin promoter, which raises the question of whether or not CRP is involved in the regulation of leukotoxin synthesis and, if so, how. To determine if CRP does indeed alter leukotoxin transcription in A. actinomycetemcomitans, we have constructed and characterized a crp mutant. Examination of leukotoxin protein and RNA production in wild type and mutant cells shows that CRP is required for leukotoxin transcription. To identify other CRP-regulated genes in A. actinomycetemcomitans, whole genome microarray analyses were done with RNA from wild type and crp mutant cells. The results indicate that hundreds of genes are CRP-regulated in A. actinomycetemcomitans and that its CRP appears to bind to the same sequences as the E. coli protein. In addition, there are several CRP-regulated transcription factors; these proteins are candidates for the molecules that CRP uses to regulate leukotoxin transcription.

2. Results

2.1 CRP is involved in leukotoxin protein and RNA synthesis

Although there are several reports suggesting that cyclic-AMP receptor protein (CRP) is involved in controlling leukotoxin synthesis in A. actinomycetemcomitans [31, 32], this hypothesis has not been directly tested. In order to prove that CRP is, or is not, involved in leukotoxin production, we identified a CRP ortholog in A. actinomycetemcomitans and constructed a crp deletion mutant in A. actinomycetemcomitans strain JP2 by allelic replacement. Wild type and crp mutant cells were grown anaerobically, in the presence of excess FeCl3 to suppress leukotoxin secretion into the media [29], and protein from whole cell lysates was analyzed by SDS-PAGE and Western blot analysis for leukotoxin production. Both experiments show that the crp mutant produces significantly less leukotoxin than wild type cells (Fig. 1). Importantly, complementation of the crp deletion with a plasmid containing only the wild type crp gene restored leukotoxin protein expression (Fig. 1) indicating that it is CRP that is involved in regulating leukotoxin production.

Fig. 1.

Fig. 1

A crp mutant makes less leukotoxin protein. Samples were taken at log phase from anaerobically grown cultures, which contained excess FeCl3, of the indicated strains. Δcrp/crp+ is the deletion strain with a crp+ plasmid in it. Cells were harvested by centrifugation, resuspended in SDS-PAGE loading buffer, boiled, centrifuged and the soluble material was electrophoresed on duplicate 7.5% SDS-polyacrylamide gels. (A) Gel stained with Coomassie Brilliant Blue. (B) Western blot analysis of total cell protein from the indicated strains. The primary antibody was rabbit anti-leukotoxin antibody. The arrow marks the position of leukotoxin (Ltx). The numbers show the positions of molecular size markers (not shown) in kD.

To see if the activation of leukotoxin expression by CRP was occurring at the level of transcription, RNA was isolated from wild type and crp mutant cells and analyzed by quantitative reverse transcriptase PCR. Consistent with the protein results, the crp mutant had a significant reduction (16.1, p ≤ 0.05 by Student’s t-test) in ltxA RNA levels (Fig. 2). This indicates that CRP is affecting leukotoxin RNA expression, most likely at the transcriptional level.

Fig. 2.

Fig. 2

Leukotoxin RNA levels are lower in the crp deletion mutant. For each sample, total cell RNA was prepared from log phase cells, cDNA was prepared with random hexamer primers and then used in real time PCR. The level of ltxA mRNA in each sample is normalized to the level of pdxY mRNA in the same sample. The data are the average of the expression ratios from five biological replicates grown as pairs. The error bars are standard deviation. As a control for RNA purity, a parallel set of samples were run without adding reverse transcriptase (RT); in each case the no RT threshold cycle appeared at least eleven cycles later than in the Ct for the corresponding sample with RT (data not shown).

2.2 Global gene expression profiling of the crp mutant

In other bacteria, CRP is a global regulator of hundreds of genes [3438]. To see if CRP is a global regulator in A. actinomycetemcomitans and to characterize its regulon, we compared the gene expression profiles of the crp deletion mutant to its wild type parent, JP2. Three hundred genes had a significant (p ≤ 0.05) change in expression of 2-fold or greater in the crp mutant (Tables S1 and S2). This number represents 14.2% of the genes probed during microarray analysis. Slightly less than half, 139, of the CRP-regulated genes are activated by CRP (Table S1). The rest (161) are repressed by CRP (Table S2). The 300 CRP-regulated genes appear to be organized into 177 operons, fifty-nine of which contain two to nine genes each. As expected from our real time-RT-PCR results with ltxA in the CRP mutant, the four genes in the leukotoxin operon [24, 39] are included in the CRP-activated set (Table S1, operon 75).

When CRP-regulated A. actinomycetemcomitans genes are categorized into seventeen classes, based broadly upon their presumed function (Oral Pathogen Sequence Databases, Los Alamos National Laboratory), every functional category has at least one gene that is CRP-regulated (Tables S3 and S4). However, there are several functional classes whose genes are disproportionately regulated by CRP, relative to their overall representation in the genome (Fig. 3). Genes in the transport and binding proteins category are clearly over-represented among both the CRP-activated and CRP-repressed genes. This is not surprising since this category includes proteins that take different sugars into cells and these types of genes are classically regulated by catabolite repression and CRP [40]. The “other categories” functional class is also over-represented in CRP-activated genes. The CRP-regulated genes in this category mainly consist of phage-related transposase or integrase genes. The CRP-repressed genes have a disproportionate number of genes in the functional category of energy metabolism and amino acid biosynthesis. The latter are mainly involved in aromatic amino acid biosynthesis and the former largely encompass genes involved in anaerobic respiration and electron transport. Finally, the combination of hypothetical and hypothetical conserved genes contains the largest number of CRP-regulated genes, but they are, overall, actually slightly under-represented among the CRP-regulated genes when you consider that they constitute more than one-third of the total number of A. actinomycetemcomitans ORFs.

Fig. 3.

Fig. 3

Proportion of CRP-regulated A. actinomycetemcomitans genes in different functional classes. The 2,363 ORFs in A. actinomycetemcomitans have been assigned to seventeen broadly defined functional categories (Oral Pathogen Sequence Databases, Los Alamos National Laboratory). Some ORFs have been assigned to two or three functional categories. The “percent in category” for “all genes” is simply the number of A. actinomycetemcomitans genes in a particular category as a percentage of the number of ORFs (2,504) in all categories. Similarly, the “percent in category” of CRP-activated and CRP-repressed genes is the number of CRP-activated (or repressed) genes in a particular functional category as a percentage of the total number of ORFs that are CRP-activated (152) or CRP-repressed (169). The total number of CRP-regulated genes is >300 in this calculation because some ORFs have been assigned to more than one functional class.

To identify the operons that are likely to be directly regulated by CRP, the sequences upstream of each of the 177 CRP-regulated operons were examined for potential CRP-binding sites [Patser score > 5.0 using the E. coli CRP binding matrix (Regulon DB)] [41]. If a potential CRP-binding site is in an intergenic region immediately upstream of an operon, it seems likely that the operon is directly regulated by CRP. As long as the putative CRP-binding site is in an intergenic region, its position relative to the translation start site was not used to exclude the CRP site as a candidate for direct activation, since it is the position of each CRP-binding site relative to the appropriate transcription start site that is critical and most of the transcription start sites have not been mapped in A. actinomycetemcomitans. Using these criteria, 37% of the CRP-activate operons (Table 1) and 36% of the CRP-repressed operons (Table 2) appear likely to be regulated directly by CRP. This represents a total of 129 genes that are likely to be regulated by CRP’s interaction with their promoters. The genes that are directly regulated by CRP do not belong predominantly to any one or two functional classes (data not shown), but are distributed across seventeen functional categories with basically the same pattern seen for the entire set of CRP-regulated genes (Fig. 3).

Table 1.

A. actinomycetemcomitans genes which have potential CRP-binding sites in intergenic regions immediately upstream of CRP-activated operons

Operon
Numbera
Gene ID Gene Information Fold
Changeb
Position of
CRP Sitec
Patser
Score
3 AA00024 Transcriptional regulatory protein 4.80 −199 5.19
AA00025 Hypothetical protein 4.74

4 AA00026 Conserved hypothetical protein 32.87 −57 6.11
AA00028 Conserved hypothetical protein (possible type III restriction- modification system
restriction subunit)
31.14
AA00029 Type III restriction-modification system: methylase 52.52
AA00030 Hypothetical protein 11.87

5 AA00031 Conserved hypothetical protein 6.32 −92 7.90
AA00033 Conserved hypothetical protein 17.26
AA00034 NTP-binding protein 51.58
AA00036 Transposase 14.55
AA00037 Conserved hypothetical protein 71.89

13 AA00497 Hexose phosphate transport system regulatory protein; regulator of uhpT
expression
2.61 −81 9.79

14 AA00592 Conserved hypothetical protein (membrane/transport protein) 2.68 −67 10.70

15 AA00632 Inner membrane protein ImpA 19.10 −320 5.29

17 AA00672 Conserved hypothetical protein (possible ppGpp-regulated growth inhibitor) 109.09 −569 5.74
AA00673 Hypothetical protein 41.13

18 AA00696 Iron(III) ABC transporter, periplasmic iron-compound-binding protein 5.91 −115 10.65
AA00698 Iron(III) ABC transporter, periplasmic iron-compound-binding protein 5.41
AA00699 Iron(III) ABC transporter,permease protein 3.11
AA00700 Cytochrome c-type biogenesis ATP-binding protein 3.12

19 AA00750 Periplasmic D-galactose-binding ABC transport protein 2.89 −155 10.88
AA00751 Cytochrome c-type biogenesis ATP-binding protein 2.78

22 AA00782 Conserved hypothetical protein (possible membrane protein) 77.19 −486 6.24
AA00785 Conserved hypothetical protein (possible integrase) 329.77

23 AA00867 Fimbrial protein Flp precursor 2.39 −143 7.07
AA00868 Possible fimbril subunit 2.37

25 AA00978 Conserved hypothetical protein 12.32 −278 5.12
AA00979 Type B carboxylesterase; p-nitrobenzyl esterase 19.08
AA00980 Hypothetical protein 34.63
AA00981 Carboxylesterase 32.21
AA00982 Aldo-keto reductase 33.78
AA00983 Aldo-keto reductase 39.01

29 AA01318 Hypothetical protein 80.42 +28 6.06

31 AA01378 Glycerol-3-phosphatase transporter 9.09 −108 11.94
AA01379 Glycerophosphoryl diester phosphodiesterase (protein D) 5.38

32 AA01383 DNA processing chain A 2.24 −83 11.67

34 AA01549 Hypothetical protein 13.65 −464 6.27
AA01550 Hypothetical protein 7.10

37 AA01692 Hexulose-6-phosphate synthase 4.18 −120 12.27
AA01694 PTS system, IIA component 5.05
AA01695 Carbohydrate transport protein 6.52

39 AA01765 Mu-like prophage FluMu transposase A 5.26 −337 7.56

41 AA01845 Gamma-glutamyltranspeptidase precursor 2.47 −100 14.79

42 AA01894 Conserved hypothetical protein (possible transthyretin-like periplasmic protein) 4.34 −83 14.45

43 AA01895 Hypothetical protein 2.48 −690 14.45
AA01896 Hypothetical protein 5.02

46 AA01902 Conserved hypothetical protein 40.60 −1626 14.42

47 AA01903 Hypothetical protein 82.03 −1027 14.42

55 AA02149 Possible transposase 35.83 −120 7.80

56 AA02150 Conserved hypothetical protein 116.05 −9 7.80

59 AA02215 Conserved hypothetical protein 4.00 −88 10.82
AA02217 Deoxyribose-phosphate aldolase 2.97
AA02218 Deoxyribose-phosphate aldolase (fragment?) 5.69
AA02219 LACI-type transcriptional regulator 3.02
AA02220 ABC transport system permease protein 4.09
AA02222 Conserved hypothetical protein 3.16
AA02224 ABC transport system permease protein 3.61
AA02225 ABC transporter ATP-binding protein 6.43
AA02226 ABC transporter ATP-binding protein 2.20

60 AA02232 NagC-like transcriptional regulator 2.98 −96 10.05

61 AA02246 Peptidase E 2.49 −83 9.83

62 AA02249 Thiamine biosynthesis protein 2.25 −133 7.25

64 AA02286 Sugar ABC transporter, ATP-binding protein 14.59 −273 12.14

67 AA02473 Conserved hypothetical protein 2.22 −122 10.64
AA02476 Conserved hypothetical protein 2.63
a

These operon numbers correspond to the operon numbers assigned in Table S1. They are not consecutive numbers in this table because a lot of operons do not have a close-by CRP-binding site and so are not included in this table.

b

Ratio (JP2/Δcrp).

c

The position of the CRP site is relative to the ATG of the first gene in the operon.

Table 2.

A. actinomycetemcomitans genes which have potential CRP-binding sites in intergenic regions immediately upstream of CRP-repressed operons

Operon
Numbera
Gene ID Gene Information Fold
Changeb
Position of
CRP Site c
Patser
Score
86 AA00069 Conserved hypothetical protein 2.02 −149 10.95

92 AA00207 Cytochrome c-type biogenesis ATP-binding protein 32.82 −87 10.81
AA00208
D-ribose ABC transporter, permease protein / Galactoside transport system
permease protein
37.42
AA00209 D-ribose ABC transporter, periplasmic-binding protein 81.55
AA00211 Hypothetical protein 110.58
AA00212 Ribokinase 45.66

94 AA00236 Anaerobic ribonucleoside-triphosphate reductase 2.08 +33 6.42

98 AA00429 Conserved hypothetical protein 5.76 −459 14.60

100 AA00452 Phosphomannomutase; phosphoglucomutase 2.36 −104 9.41

104 AA00634 DNA polymerase IV (Pol IV) 13.15 −38 5.13

105 AA00663 Cystathionine beta-lyase 2.36 −33 7.00

109 AA00781 Hypothetical protein 8.92 −106 6.19

120 AA01135 Possible cell filamentation protein 3.92 −131 5.47

121 AA01137 Anaerobic dimethyl sulfoxide reductase, chain A 2.18 −80 11.44
AA01138 Anaerobic dimethyl sulfoxide reductase, chain B 2.33
AA01141 Conserved hypothetical protein (possible component of anaerobic
dehydrogenase/oxidoreductase)
2.43

129 AA01455 D-xylose ABC transporter, ATP-binding protein 3.18 −150 10.70
AA01456 D-xylose ABC transporter, ATP-binding protein 2.35

130 AA01465 Mannose-specific phosphotransferase element 2.05 −100 14.46
AA01466 Mannose-specific phosphotransferase system IIC 2.08
AA01467 Mannose-specific phosphotransferase system IID 2.11

131 AA01544 Conserved hypothetical protein 2.50 −65 9.71

134 AA01696 Conserved hypothetical protein 2.88 −226 12.27
AA01698 Probable transcriptional regulator (DeoR family) 2.10

136 AA01717 Fumarate hydratase, class II 2.21 −100 10.16

141 AA01875 PTS system, glucose-specific enzyme II, A component 2.08 −121 9.26
AA01876 PTS system, IIBC components 2.52

143 AA01918 Anaerobic C4-dicarboxylate transporter 2.21 −94 9.72

144 A01923 Type III restriction-modification system methylation subunit 6.37 −78 5.76
AA01928 ATP-dependent RNA helicase 4.78

145 AA01938 NAD(P) transhydrogenase subunit alpha 2.01 −142 8.07

146 AA01944 Conserved hypothetical protein 2.10 −186 5.53

153 AA02193 Oxaloacetate decarboxylase gamma chain 2.39 −69 10.15
AA02195 Oxaloacetate decarboxylase alpha chain 2.30
AA02196 Oxaloacetate decarboxylase beta chain 3.33

154 AA02201 Transferrin-binding protein 1 precursor 21.99 −44 5.32
AA02202 Transferrin-binding protein 1 prcursor 41.76

156 AA02210 Ribonucleoside-diphosphate redctase alpha chain 3.35 −61 10.09
AA02212 Ribonucleoside-diphosphate redctase beta chain 4.59

157 AA02237 Molybdopterin biosynthesis proein E chain 4.15 −198 7.38
AA02239 Molybdopterin biosynthesis proein D 3.80
AA02241 Molybdenum cofactor biosynthsis protein C 4.46
AA02242 Molybdenum cofactor biosythesis protein A 3.90

158 AA02250 Possible cytochrome c-type protein 13.14 −101 6.40
AA02251 Biotin sulfoxide reductase; rimethylamine-N-oxide reductase precursor 15.92

162 AA02393 Conserved hypothetical protein; possible sulfate transporter 2.42 −115 5.11

166 AA02577 Nuclease 4.82 −297 8.88
AA02579 Aminotransferase nifS protein 3.68

168 AA02671 Glucononase 2.11 −131 11.29

169 AA02683 Hydrogenase 4 Fe-S subunit 3.08 −101 8.01
AA02687 Hydrogenase-4 component D 3.29
AA02688 Hydrogenase 4 component E 4.02
AA02689 Hydrogenase-4 component F 3.46
AA02692 Hydrogenase 4 subunit; hydrogenase 3 subunit 4.70
AA02693 Hydrogenase-4 component H 2.81
AA02696 Formate hydrogenlyase maturation protein 3.92
AA02697 Hydrogenase 3 maturation protease 4.26

171 AA02726 Anaerobic C4-dicarboxylate transporter 2.34 −100 5.48

172 AA02756 Phosphoserine aminotransferase 5.47 −140 9.51
AA02757 Histidinol-phosphate aminotransferase 2 5.22
AA02758 3-phosphoshikimate 1-carboxyvinyltransferase 2.68

173 AA02768 Conserved hypothetical protein 2.66 −399 10.14

174 AA02772 Hypothetical protein 2.53 −119 10.74

175 AA02784 NAD+ dependent acetaldehyde-alcohol dehydrogenase, iron-containing 3.59 −70 10.46
a

These operon numbers correspond to the operon numbers assigned in Table S1. They are not consecutive numbers in this table because a lot of operons do not have a close-by CRP-binding site and so are not included in this table.

b

Ratio (Δcrp/JP2).

c

The position of the CRP site is relative to the ATG of the first gene in the operon.

Is an intergenic CRP-binding site a good prediction of CRP-regulation in our experiment? Apparently not. There are 77 intergenic CRP-binding sites (Patser score ≥ 10) in the entire A. actinomycetemcomitans genome. But only 19 (25%) of the genes adjacent to those CRP sites are CRP-regulated in our microarray experiment. This seemingly large percentage of CRP-binding sites that appear to be non-functional most likely represents the involvement of additional transcription factors at a lot of CRP-regulated genes under the conditions tested rather than the inability of these sites to bind CRP and alter transcription. This can be tested, in part, by additional expression array experiments with cells grown under different conditions where other transcription factors may play a less dominant role.

3. Discussion

Inoue et al. showed by Northern blot analysis that leukotoxin RNA levels decreased in response to increased fructose in the media [32]. Since this effect could be reversed by the addition of cAMP to the media, it was hypothesized, but not proven, that this regulation occurs via the classical cAMP/CRP regulatory pathway [33]. In this pathway, when glucose is present, the CRP protein is inactive and unable to bind DNA. However, when glucose is depleted cAMP is synthesized by the cell and it binds to and activates CRP. The active cAMP/CRP complex can then bind to its genomic binding sites and activate or repress the transcription of adjacent operons. In this report, we have clearly shown that CRP does regulate leukotoxin transcription since leukotoxin RNA levels decrease 16-fold in a CRP deletion mutant. Although our experiments were done in JP2, a highly leukotoxic strain, CRP will almost certainly activate leukotoxin transcription in other strains of A. actinomycetemcomitans, even those that have the 528 bp deletion in the 5’-non-coding region of the leukotoxin operon and express overall lower levels of leukotoxin, because (1) the strain, 301-b, Inoue et al [32] used to show that leukotoxin transcription is activated by cAMP (and thus presumably activated by CRP) has the 528 bp deletion in the leukotoxin mRNA leader but is identical to JP2 in the leukotoxin promoter region, and, (2) the leukotoxin promoter regions are identical among most strains of A. actinomycetemcomitans [24, 42, 43] or vary, in one strain, by a few bases [25]. However, the mechanism by which CRP activates leukotoxin transcription is unclear since the leukotoxin promoter does not have a sequence resembling the CRP-consensus binding sequence [33, 44]; the best match in the leukotoxin promoter region has an extremely low Patser score of 3.7. This suggests that either cAMP/CRP is binding to a non-consensus sequence or it is acting indirectly at leukotoxin by regulating another transcription factor. Since the A. actinomycetemcomitans CRP protein sequence is 86% identical to that of the E. coli protein and since our microarray results show that a number of genes with close-to-consensus CRP-binding sites in their promoters are mis-regulated in our CRP mutant, we favor the latter possibility. In fact, eleven genes encoding possible DNA binding protein/transcription or regulatory factors are regulated by CRP in A. actinomycetemcomitans. We are currently investigating the possibility that one of these proteins may be the intermediary between CRP and its regulation of leukotoxin transcription.

In other bacteria, catabolite repression is a global regulatory mechanism that alters the transcription of numerous genes, especially those needed for utilization of non-glucose carbon sources [33, 45]. We have used microarray expression analysis to show that at least 14% of the genes in A. actinomycetemcomitans are CRP regulated either directly (6%) or indirectly (8%). This is significantly higher than what has been reported for other bacteria. In Vibrio cholerae, Yersinia pestis and E. coli, <7% of each organism’s genes were CRP-regulated in microarray experiments [35, 37, 38]. The biological relevance of this difference is unclear since the growth parameters used with V. cholerae and Y. pestis were quite different and the E. coli results had the additional constraint that the CRP-regulated genes must also be glucose regulated. However, it is interesting to speculate that CRP regulates more genes in A. actinomycetemcomitans because, as the only oral organism examined, it needs to deal with more frequent changes in the carbohydrates seen than do the non-oral bacteria examined by microarrays. Despite the differences in the overall number of genes regulated by CRP in the different bacteria using different experimental parameters, the proportions of functional categories of genes that are CRP-regulated are very similar. For example, in V. cholerae and A. actinomycetemcomitans, which both used the same classification scheme to put genes into seventeen functional categories, the majority of CRP-regulated genes belong to one of three categories: transport/binding proteins, energy metabolism or hypothetical/hypothetical conserved (compare our Fig. 3 to Fig. 1 in reference [37]).

Sixty different genes appear to be regulated directly by CRP in E. coli [3436] and/or Y. pestis [38]. However, only one of these genes, ptsG, appears to be regulated directly by CRP in all three organisms (A. actinomycetemcomitans, E. coli, and Y. pestis). In addition, the malX gene and mglBAC operon appear to be regulated directly by CRP in E. coli and A. actinomycetemcomitans. This result seems somewhat surprising since the overall classes of genes regulated by CRP seems so similar, but 35 of the 60 genes that are regulated directly by CRP in E. coli or Y. pestis do not have homologues in A. actinomycetemcomitans. Once again this likely reflects the different ecological niches in which these organisms are found. Of the 25 genes that do have A. actinomycetemcomitans homologues, 19 are not CRP-regulated in A. actinomycetemcomitans. Of course, the caveat “not CRP-regulated in the conditions tested” must be added, especially in light of the fact that 9 of the A. actinomycetemcomitans homologues of directly regulated E. coli or Y. pestis genes have a good CRP-binding site (Patser score > 8.0) in their promoter regions and thus may actually be regulated directly by CRP in different growth conditions. This possibility is being examined.

In summary, microarray analysis of a crp mutant was used to define the CRP regulon of A. actinomycetemcomitans. The data indicates that, while the percentage of CRP-regulated genes is higher in A. actinomycetemcomitans than other bacteria, the distribution of these genes among functional categories is similar to patterns seen in other bacteria. This study also proved that CRP regulates leukotoxin production at the transcriptional level although this most likely occurs through some intermediary protein. We have identified candidate genes for this intermediary factor which are currently being investigated for their roles in leukotoxin regulation.

4. Materials and Methods

4.1 Bacterial strains and culture conditions

A. actinomycetemcomitans strain JP2 [23] was used in this study. JP2, a serotype b strain, was originally isolated from a young patient with periodontitis and it expresses high levels of leukotoxin due to a 528 bp deletion in the 5’-non-coding region of the leukotoxin operon [24, 25]. Cells were grown anaerobically (5% CO2, 10% H2, 85% N2) in a Coy chamber (Coy Laboratory Products, Ann Arbor, MI) at 37°C with sh aking in TSBYE (3% tryptic soy broth plus 0.6% yeast extract). The recombinant constructs were propagated in E. coli TB-1 at 37°C in Luria broth [46]. Where indicated, FeCl3 was added to a final concentration of 300 µM, ampicillin was added to a final concentration of 100 µg/ml, spectinomycin to a final concentration of 100 µg/ml or chloramphenicol to a final concentration of 5 µg/ml.

4.2 Construction of a crp deletion mutant in A. actinomycetemcomitans

To construct a crp deletion mutant, PCR and standard recombinant DNA techniques were used to construct plasmid pDK936, in which 0.98 kb of DNA immediately upstream of crp and 0.94 kb of the DNA immediately downstream of crp flank a 1.1 kb spectinomycin resistance gene [47] in place of the crp coding region. The plasmid, which is pUC-based and does not replicate in A. actinomycetemcomitans, contains sacB as a counterselectable marker [48]. Plasmid pDK936 was electroporated into A. actinomycetemcomitans strain JP2. Spectinomycin resistant colonies, resulting from a single crossover event at the crp locus, were selected. By subsequently plating the spectinomycin resistant cells onto TSBYE plus 10% sucrose, cells in which a second recombination event occurred, such that the vector is removed from the chromosome along with the wild type crp gene, were selected. PCR was used to confirm that the genomic crp gene had been replaced by the spectinomycin resistance allele in these spectinomycin-resistant, sucrose-resistant colonies, and one isolate, AAM167, was used in subsequent experiments.

4.3 Complementation of the crp deletion mutant

Standard recombinant DNA techniques and PCR were used to construct plasmid pDK937, a crp complementing plasmid. This DNA contains 319 bp of the region immediately upstream of crp, the entire crp gene and 48 bp of the DNA immediately downstream of crp, all cloned into pDK937 which is a derivative of the integrating plasmid pJM102 [49] that contains a chloramphenicol resistance gene. This plasmid was electroporated into AAM167 and the resulting chloramphenicol resistant colonies were shown to result from a single recombination event at the crp locus by PCR analysis. One isolate, AAM168, was used in subsequent experiments.

4.4 Analysis of leukotoxin protein

Cells from log phase cultures, grown with 300 µM FeCl3, of A. actinomycetemcomitans strains JP2, AAM167 and AAM168 were collected by centrifugation. Total protein was prepared by suspending equal numbers of cells in 50 µl 1× loading buffer (1% SDS, 10% glycerol, 6 mM Tris, pH 6.8, 5% β-mercaptoethanol, and 0.01% bromophenol blue) and heating at 100°C for 2 min. The samples were clarified by centrifuging 5 min and equal amounts of each sample were electrophoresed on duplicate 7.5% SDS-polyacrylamide gels. Protein was visualized on one gel using Coomassie brilliant blue. The proteins from the other gel were electrophoretically transferred to a nitrocellulose membrane (Hoefer, Inc, Holliston, MA) using CAPS buffer (10 mM CAPS, 3.24 mM DTT, 1% methanol) for Western blot analysis. After blocking for 1 h with blocking solution, diluted (1:2000) rabbit polyclonal anti-leukotoxin antibody was added to the nitrocellulose filter for 2 h, followed by the addition of a 1:5000 dilution of goat-anti-rabbit IgG whole molecule Horseradish peroxidase (HRP) conjugate (Sigma, St. Louis, MO). HRP color developing reagent (Bio-Rad, Hercules, CA) was used to develop the Western.

4.5 Analysis of RNA expression

RNA was isolated from mid-log phase A. actinomycetemcomitans cells using RNAprotect® Bacterial Reagent (Qiagen, Inc., Valencia, CA) and the RNeasy® Mini Kit (Qiagen). The manufacturer’s instructions were followed with the following notes: 2.5 ml of cells were lysed with 10 mg/ml lysozyme (Sigma, St. Louis, MO) for 15 min. The RNase-free DNase Set (Qiagen) was used to remove DNA. Each RNA sample (400 ng) was converted into cDNA with the Omniscript® Reverse Transcriptase kit (Qiagen) and random hexamer primers (Qiagen). Real time PCR was performed in triplicate on 1/1600 dilutions of cDNAs with GoTaq® qPCR Master Mix (Promega, Madison. WI) and appropriate primers (300 nM for lkt516, lkt517, lkt519; 900 nM for lkt518). The reactions were monitored on a Chromo4 Real-Time PCR Detection System (Bio-Rad, Hercules, CA); an initial denaturation step of 2 min at 95°C was followed by 39 cycles of amplification (15 s at 95°C, 1 min at 63°C, read plate). A melting curve of the reaction products was done at the completion of the PCR to show that the expected PCR product was the only one amplified. The level of ltxA mRNA in a given sample was normalized to the level of pdxY mRNA in the same sample by calculating the difference in the averaged ltxA and pdxY threshold cycles (Ct) for that sample. The following primer pairs were used: lkt516 (5’-CGAGGGAAGGTTACCGATCTAC-3’) and lkt517 (5’-TGCTGCCGATAATTTCCTCTAC-3’) amplify a 119 bp fragment from the middle of the leukotoxin gene and primers lkt518 (5’-CAAAAGCCTCCACATCGGAT-3’) and lkt519 (5’-CGTTGGCGTGGGTGATTTAAC-3’) amplify a 77 bp fragment from the pdxY gene. This gene is not regulated in multiple microarray experiments of cells grown under various conditions (data not shown).

For microarray analysis, 50 µg of each RNA sample was sent on dry ice to Roche NimbleGen (Madison, WI) where the RNA was made into Cy3-labeled cDNA using random hexamers and hybridized to a custom A. actinomycetemcomitans array. The microarrays, designed and synthesized by Roche NimbleGen, were based on the sequence and annotation data for A. actinomycetemcomitans strain HK1651 (Oral Pathogen Sequence Databases, Los Alamos National Laboratories). The arrays were scanned at Roche NimbleGen and the expression values were sent back to UTHSCSA. Each array had 60-mer probes for 2,116 genes and there were 11 different probes/gene for almost all (94%) of the ORFs. In addition, this entire probe set was replicated three times on each array and there were 4,426 random probes per array.

4.6 Statistical analysis

Robust Multi-Array Analysis (RMA) [50] in the NimbleScan Software Package (v2.5, Roche NimbleGen, Madison, WI) was used to do background corrections of expression data from individual arrays, to then do quantile normalization [51] across the arrays being compared and to reduce the contribution of outlier probes to the single expression value derived from multiple probes for a given gene on a given array. The corrected expression values from three biological replicates of JP2 were compared to those from three biological replicates of AAM167 by performing student t-tests on the log 2 transformed data using the Multi Experiment Viewer (http://www.tm4.org/mev) [52]. Genes whose expression levels changed by at least 2-fold with p ≤ 0.05 were considered significant.

4.7 Accession number

The microarray data is available online at the National Center for Biotechnology Information Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) and is MIAME-compliant. Its accession number is GSE25459.

4.8 Assigning genes to operons

Two or more ORFs are considered to be in an operon if they are in the same orientation and are not separated by any intergenic regions longer than 50 bp in length. If an intergenic sequence between two same-orientation ORFs was longer than 50 bp, the Neural Network Promoter Prediction (http://www.fruitfly.org/seq_tools/promoter.html) and BPROM (http://linux1.softberry.com/berry.phtml) programs were used to identify potential σ70 promoters in the intergenic region. If both programs predicted that there was a correctly oriented σ70 promoter, then the downstream ORF was assigned to a new operon, instead of being designated part of an operon with the upstream gene.

Acknowledgements

This work was supported by the Public Health Service Grants T32-DE14318 and DE15625 from the National Institutes of Health.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1. List of genes, organized into operons, that are CRP-activated (≥ 2-fold) in A. actinomycetemcomitans

Table S2. List of genes, organized into operons, that are CRP-repressed (≥ 2-fold) in A. actinomycetemcomitans

Table S3. Genes significantly induced (≥ 2-fold) by CRP in A. actinomycetemcomitans, organized by functional class

Table S4. Genes significantly repressed (≥ 2-fold) by CRP in A. actinomycetemcomitans, organized by functional class

References

  • 1.Nørskov-Lauritsen N, Kilian M. Reclassification of Actinobacillus actinomycetemcomitans, Haemophilus aphrophilus, Haemophilus paraphrophilus and Haemophilus segnis as Aggregatibacter actinomycetemcomitans gen. nov., comb. nov., Aggregatibacter aphrophilus comb. nov. and Aggregatibacter segnis comb. nov., and emended description of Aggregatibacter aphrophilus to include V factor-dependent and V factor-independent isolates. Int J Syst Evol Microbiol. 2005;56:2135–2146. doi: 10.1099/ijs.0.64207-0. [DOI] [PubMed] [Google Scholar]
  • 2.Slots J, Ting M. Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in human periodontal disease: occurrence and treatment. Periodontol 2000. 1999;20:82–121. doi: 10.1111/j.1600-0757.1999.tb00159.x. [DOI] [PubMed] [Google Scholar]
  • 3.van Winkelhoff AJ, Slots J. Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in nonoral infections. Periodontol 2000. 1999;20:122–135. doi: 10.1111/j.1600-0757.1999.tb00160.x. [DOI] [PubMed] [Google Scholar]
  • 4.Mitchell RG, Gillespie WA. Bacterial Endocarditis due to an actinobacillus. J Clin Pathol. 1964;17:511–512. doi: 10.1136/jcp.17.5.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Slots J. The predominant cultivable organisms in juvenile periodontitis. Scand J Dent Res. 1976;84:1–10. doi: 10.1111/j.1600-0722.1976.tb00454.x. [DOI] [PubMed] [Google Scholar]
  • 6.Zambon JJ. Actinobacillus actinomycetemcomitans in human periodontal disease. J Clin Periodontol. 1985;12:1–20. doi: 10.1111/j.1600-051x.1985.tb01348.x. [DOI] [PubMed] [Google Scholar]
  • 7.Henderson B, Ward JM, Ready D. Aggregatibacter (Actinobacillus) actinomycetemcomitans: a triple A* periodontopathogen? Periodontol 2000. 2010;54:78–105. doi: 10.1111/j.1600-0757.2009.00331.x. [DOI] [PubMed] [Google Scholar]
  • 8.Fine DH, Kaplan JB, Kachlany SC, Schreiner HC. How we got attached to Actinobacillus actinomycetemcomitans: a model for infectious diseases. Periodontol 2000. 2006;42:114–157. doi: 10.1111/j.1600-0757.2006.00189.x. [DOI] [PubMed] [Google Scholar]
  • 9.Kinane DF, Mooney J, Ebersole JL. Humoral immune response to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in periodontal disease. Periodontol 2000. 1999;20:289–340. doi: 10.1111/j.1600-0757.1999.tb00164.x. [DOI] [PubMed] [Google Scholar]
  • 10.Fives-Taylor PM, Meyer DH, Mintz KP, Brissette C. Virulence factors of Actinobacillus actinomycetemcomitans. Periodontol 2000. 1999;20:136–167. doi: 10.1111/j.1600-0757.1999.tb00161.x. [DOI] [PubMed] [Google Scholar]
  • 11.Henderson B, Nair SP, Ward JM, Wilson M. Molecular pathogenicity of the oral opportunistic pathogen Actinobacillus actinomycetemcomitans. Annu Rev Microbiol. 2003;57:29–55. doi: 10.1146/annurev.micro.57.030502.090908. [DOI] [PubMed] [Google Scholar]
  • 12.Tsai CC, McArthur WP, Baehni PC, Hammond BF, Taichman NS. Extraction and partial characterization of a leukotoxin from a plaque-derived gram-negative microorganism. Infect Immun. 1979;25:427–439. doi: 10.1128/iai.25.1.427-439.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kachlany SC. Aggregatibacter actinomycetemcomitans leukotoxin: from threat to therapy. J Dent Res. 2010;89:561–570. doi: 10.1177/0022034510363682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Haubek D. The highly leukotoxic JP2 clone of Aggregatibacter actinomycetemcomitans: evolutionary aspects, epidemiology and etiological role in aggressive periodontitis. Acta Pathologica, Microbiologica et Immunologica Scandinavica. 2010;118 Suppl 130:1–53. doi: 10.1111/j.1600-0463.2010.02665.x. [DOI] [PubMed] [Google Scholar]
  • 15.Taichman NS, Wilton JM. Leukotoxicity of an extract from Actinobacillus actinomycetemcomitans for human gingival polymorphonuclear leukocytes. Inflammation. 1981;5:1–12. doi: 10.1007/BF00910774. [DOI] [PubMed] [Google Scholar]
  • 16.Lally ET, Kieba IR, Sato A, Green CL, Rosenbloom J, Korostoff J, et al. RTX toxins recognize a β2 integrin on the surface of human target cells. J Biol Chem. 1997;272:30463–30469. doi: 10.1074/jbc.272.48.30463. [DOI] [PubMed] [Google Scholar]
  • 17.Johansson A, Sandström G, Claesson R, Hänström L, Kalfas S. Anaerobic neutrophil-dependent killing of Actinobacillus actinomycetemcomitans in relation to the bacterial leukotoxicity. Eur J Oral Sci. 2000;108:136–146. doi: 10.1034/j.1600-0722.2000.00790.x. [DOI] [PubMed] [Google Scholar]
  • 18.Venketaraman V, Lin AK, Le A, Kachlany SC, Connell ND, Kaplan JB. Both leukotoxin and poly-N-acetylglucosamine surface polysaccharide protect Aggregatibacter actinomycetemcomitans cells from macrophage killing. Microb Pathog. 2008;45:173–180. doi: 10.1016/j.micpath.2008.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Balashova NV, Crosby JA, Al Ghofaily L, Kachlany SC. Leukotoxin confers beta-hemolytic activity to Actinobacillus actinomycetemcomitans. Infect Immun. 2006;74:2015–2021. doi: 10.1128/IAI.74.4.2015-2021.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Korostoff J, Wang JF, Kieba I, Miller M, Shenker BJ, Lally ET. Actinobacillus actinomycetemcomitans leukotoxin induces apoptosis in HL-60 cells. Infect Immun. 1998;66:4474–4483. doi: 10.1128/iai.66.9.4474-4483.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Kelk P, Claesson R, Chen C, Sjöstedt A, Johansson A. IL-1β secretion induced by Aggregatibacter (Actinobacillus) actinomycetemcomitans is mainly caused by the leukotoxin. Int J Med Microbiol. 2008;298:529–541. doi: 10.1016/j.ijmm.2007.06.005. [DOI] [PubMed] [Google Scholar]
  • 22.Kelk P, Abd H, Claesson R, Sandström G, Sjöstedt A, Johansson A. Cellular and molecular response of human macrophages exposed to Aggregatibacter actinomycetemcomitans leukotoxin. Cell Death Dis. 2011;2:e126. doi: 10.1038/cddis.2011.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Tsai CC, Shenker BJ, DiRienzo JM, Malamud D, Taichman NS. Extraction and isolation of a leukotoxin from Actinobacillus actinomycetemcomitans with polymyxin B. Infect Immun. 1984;43:700–705. doi: 10.1128/iai.43.2.700-705.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Brogan JM, Lally ET, Poulsen K, Kilian M, Demuth DR. Regulation of Actinobacillus actinomycetemcomitans leukotoxin expression: analysis of the promoter regions of leukotoxic and minimally leukotoxic strains. Infect Immun. 1994;62:501–508. doi: 10.1128/iai.62.2.501-508.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kolodrubetz D, Spitznagel J, Jr, Wang B, Phillips LH, Jacobs C, Kraig E. cis elements and trans factors are both important in strain-specific regulation of the leukotoxin gene in Actinobacillus actinomycetemcomitans. Infect Immun. 1996;64:3451–3460. doi: 10.1128/iai.64.9.3451-3460.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Spitznagel J, Jr, Kraig E, Kolodrubetz D. The regulation of leukotoxin production in Actinobacillus actinomycetemcomitans strain JP2. Adv Dent Res. 1995;9:48–54. doi: 10.1177/08959374950090010901. [DOI] [PubMed] [Google Scholar]
  • 27.Kolodrubetz D, Phillips L, Jacobs C, Burgum A, Kraig E. Anaerobic regulation of Actinobacillus actinomycetemcomitans leukotoxin transcription is ArcA/FnrA-independent and requires a novel promoter element. Res Microbiol. 2003;154:645–653. doi: 10.1016/j.resmic.2003.09.001. [DOI] [PubMed] [Google Scholar]
  • 28.Fong KP, Chung WO, Lamont RJ, Demuth DR. Intra- and interspecies regulation of gene expression by Actinobacillus actinomycetemcomitans LuxS. Infect Immun. 2001;69:7625–7634. doi: 10.1128/IAI.69.12.7625-7634.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Balashova NV, Diaz R, Balashov SV, Crosby JA, Kachlany SC. Regulation of Aggregatibacter (Actinobacillus) actinomycetemcomitans leukotoxin secretion by iron. J Bacteriol. 2006;188:8658–8661. doi: 10.1128/JB.01253-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Isaza MP, Duncan MS, Kaplan JB, Kachlany SC. Screen for leukotoxin mutants in Aggregatibacter actinomycetemcomitans: genes of the phosphotransferase system are required for leukotoxin biosynthesis. Infect Immun. 2008;76:3561–3568. doi: 10.1128/IAI.01687-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Mizoguchi K, Ohta H, Miyagi A, Kurihara H, Takashiba S, Kato K, et al. The regulatory effect of fermentable sugar levels on the production of leukotoxin by Actinobacillus actinomycetemcomitans. FEMS Microbiol Lett. 1997;146:161–166. doi: 10.1111/j.1574-6968.1997.tb10187.x. [DOI] [PubMed] [Google Scholar]
  • 32.Inoue T, Tanimoto I, Tada T, Ohashi T, Fukui K, Ohta H. Fermentable-sugar-level-dependent regulation of leukotoxin synthesis in a variably toxic strain of Actinobacillus actinomycetemcomitans. Microbiology. 2001;147:2749–2756. doi: 10.1099/00221287-147-10-2749. [DOI] [PubMed] [Google Scholar]
  • 33.Kolb A, Busby S, Buc H, Garges S, Adhya S. Transcriptional regulation by cAMP and its receptor protein. Annu Rev Biochem. 1993;62:749–795. doi: 10.1146/annurev.bi.62.070193.003533. [DOI] [PubMed] [Google Scholar]
  • 34.Gosset G, Zhang Z, Nayyar S, Cuevas WA, Saier MH., Jr Transcriptome analysis of Crp-dependent catabolite control of gene expression in Escherichia coli. J Bacteriol. 2004;186:3516–3524. doi: 10.1128/JB.186.11.3516-3524.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Zheng D, Constantinidou C, Hobman JL, Minchin SD. Identification of the CRP regulon using in vitro and in vivo transcriptional profiling. Nucleic Acids Res. 2004;32:5874–5893. doi: 10.1093/nar/gkh908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Hollands K, Busby SJ, Lloyd GS. New targets for the cyclic AMP receptor protein in the Escherichia coli K-12 genome. FEMS Microbiol Lett. 2007;274:89–94. doi: 10.1111/j.1574-6968.2007.00826.x. [DOI] [PubMed] [Google Scholar]
  • 37.Liang W, Pascual-Montano A, Silva AJ, Benitez JA. The cyclic AMP receptor protein modulates quorum sensing, motility and multiple genes that affect intestinal colonization in Vibrio cholerae. Microbiology. 2007;153:2964–2975. doi: 10.1099/mic.0.2007/006668-0. [DOI] [PubMed] [Google Scholar]
  • 38.Zhan L, Han Y, Yang L, Geng J, Li Y, Gao H, et al. The cyclic AMP receptor protein, CRP, is required for both virulence and expression of the minimal CRP regulon in Yersinia pestis biovar microtus. Infect Immun. 2008;76:5028–5037. doi: 10.1128/IAI.00370-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Spitznagel J, Jr, Kraig E, Kolodrubetz D. Regulation of leukotoxin in leukotoxic and nonleukotoxic strains of Actinobacillus actinomycetemcomitans. Infect Immun. 1991;59:1394–1401. doi: 10.1128/iai.59.4.1394-1401.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Görke B, Stülke J. Carbon catabolite repression in bacteria: many ways to make the most out of nutrients. Nat Rev Microbiol. 2008;6:613–624. doi: 10.1038/nrmicro1932. [DOI] [PubMed] [Google Scholar]
  • 41.Gama-Castro S, Jiménez-Jacinto V, Peralta-Gil M, Santos-Zavaleta A, Peñaloza-Spinola MI, Contreras-Moreira B, et al. RegulonDB (version 6.0): gene regulation model of Escherichia coli K-12 beyond transcription, active (experimental) annotated promoters and Textpresso navigation. Nucleic Acids Res. 2008;36:D120–D124. doi: 10.1093/nar/gkm994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Saddi-Ortega L, Carvalho MA, Cisalpino PS, Moreira ES. Actinobacillus actinomycetemcomitans genetic heterogeneity: amplification of JP2-like ltx promoter pattern correlated with specific arbitrarily primed polymerase chain reaction (AP-PCR) genotypes from human but not marmoset Brazilian isolates. Can J Microbiol. 2002;48:602–610. doi: 10.1139/w02-055. [DOI] [PubMed] [Google Scholar]
  • 43.Chen C, Kittichotirat W, Si Y, Bumgarner R. Genome sequence of Aggregatibacter actinomycetemcomitans serotype c strain D11S-1. J Bacteriol. 2009;191:7378–7379. doi: 10.1128/JB.01203-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Jansen C, Gronenborn AM, Clore GM. The binding of the cyclic AMP receptor protein to synthetic DNA sites containing permutations in the consensus sequence TGTGA. Biochem J. 1987;246:227–232. doi: 10.1042/bj2460227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Deutscher J, Francke C, Postma PW. How phosphotransferase system-related protein phosphorylation regulates carbohydrate metabolism in bacteria. Microbiol Mol Biol Rev. 2006;70:939–1031. doi: 10.1128/MMBR.00024-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Seidman CE, Struhl K, Sheen J, Jessen T. Introduction of plasmid DNA into cells. Curr Protoc Mol Biol. 1997;37:1.8.1–2. doi: 10.1002/0471142727.mb0108s37. [DOI] [PubMed] [Google Scholar]
  • 47.LeBlanc DJ, Lee LN, Inamine JM. Cloning and nucleotide base sequence analysis of a spectinomycin adenyltransferase AAD(9) determinant from Enterococcus faecalis. Antimicrob Agents Chemother. 1991;35:1804–1810. doi: 10.1128/aac.35.9.1804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Reyrat JM, Pelicic V, Gicquel B, Rappuoli R. Counterselectable markers: untapped tools for bacterial genetics and pathogenesis. Infect Immun. 1998;66:4011–4017. doi: 10.1128/iai.66.9.4011-4017.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Ferrari E, Hoch JA. Genetics. In: Harwood CR, editor. Bacillus. New York, NY: Plenum Press; 1989. pp. 57–72. [Google Scholar]
  • 50.Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249–264. doi: 10.1093/biostatistics/4.2.249. [DOI] [PubMed] [Google Scholar]
  • 51.Bolstad BM, Irizarry RA, Åstrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185–193. doi: 10.1093/bioinformatics/19.2.185. [DOI] [PubMed] [Google Scholar]
  • 52.Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, et al. TM4 microarray software suite. Methods Enzymol. 2006;411:134–193. doi: 10.1016/S0076-6879(06)11009-5. [DOI] [PubMed] [Google Scholar]

RESOURCES